Sector News

Melinta’s CEO steps down amid a big Phase III push

September 14, 2015
Life sciences

Melinta Therapeutics CEO Mary Szela has left the company in the middle of a late-stage program for its lead antibiotic, a move that comes just months after the biotech raised $67 million in equity financing.

Szela stepped down earlier this month, according to Melinta, ending a tenure that began in April 2013. The company’s board “decided to make a change,” Melinta Senior Vice President Lyn Baranowski said, and Szela left “under very amicable circumstances.”

The company didn’t provide any further details behind her departure, and Szela didn’t respond to a request for comment. Eugene Sun, Melinta’s head of R&D, is now serving as interim CEO, Melinta said.

The shakeup comes amid an all-important clinical effort for Melinta, which is working through a Phase III trial with delafloxacin, a treatment for acute bacterial skin and skin-structure infections (ABSSSIs). Last year, the company abandoned an effort to develop delafloxacin in gonorrhea, pivoting to ABSSSIs and launching a Phase III study to confirm its potential. Now Melinta says it’s on track to wrap up that trial early next year and potentially submit the drug for FDA approval shortly thereafter.

To pay delafloxacin’s way, the New Haven, CT, company raised $67 million in June, tapping high-profile biotech backer Malin to get the cash it needs to move toward commercialization.

Melinta, then Rib-X, recruited Szela in 2013 to spearhead delafloxacin’s development, part of a wave of management changes spurred by major investor Vatera Healthcare Partners. The company, under its old name, was a 2011 Fierce 15 honoree.

Szela spent nearly 25 years at Abbott Laboratories before joining Melinta. She remains a member of the boards of Novo Nordisk, Coherus BioSciences and Suneva Medical.

By Damian Garde

Source: Fierce Biotech

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach